The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

We are poised for the market with a clinical pipeline that includes three novel products in late-stage development: Albuferon® in Phase 3 trials for hepatitis C, LymphoStat-B® in Phase 3 trials for systemic lupus, and ABthrax™ in late-stage development for inhalation anthrax.

Both Albuferon and LymphoStat-B have the therapeutic potential to change and save lives and the commercial potential to become blockbusters in the marketplace. Each is being co-developed and commercialized in collaboration with a world leader in the pharmaceutical industry – Novartis for Albuferon and GlaxoSmithKline (GSK) for LymphoStat-B.

ABthrax is being developed under a contract with the U.S. Government and represents a new way to address the threat of inhalation anthrax. The pivotal efficacy studies have demonstrated a dramatic and significant survival benefit, and we are manufacturing on schedule to begin delivery of ABthrax to the Strategic National Stockpile by fall 2008.

Right behind these three late-stage products is a high-potential mid-stage pipeline led by our TRAIL receptor antibodies for cancer – and including a number of products to which HGS has substantial financial rights in the GSK pipeline.

Our manufacturing capability represents a significant strategic advantage. HGS is able to produce and purify multiple protein and antibody drugs in two state-of-the-art process development and manufacturing facilities – totaling approximately 400,000 square feet and offering both small-scale and large-scale production.

Unlike many pre-commercial biopharmaceutical companies, HGS has built a strong cash position that allows us to focus on advancing our lead products toward commercialization as rapidly as possible, while at the same time investing in our early- and mid-stage pipeline. We are committed to achieving and sustaining growth well into the future.